Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION In a biologics company planning a biosimilar pathway, phase-3 protocol with endpoint-sensitivity issues is the evidence after a payer demanding RWE the protocol cannot generate. Clinical-development physician has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy close using phase-3 protocol with endpoint-sensitivity issues.

DECISION Clinical-development physician in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after a payer demanding RWE the protocol cannot generate.

HYPOTHESES TO TEST 1. The population in phase-3 protocol with endpoint-sensitivity issues is the one a payer demanding RWE the protocol cannot generate named, so Proceed under protocol follows for this Clinical and Evidence Strategy file. 2. The population in phase-3 protocol with endpoint-sensitivity issues is adjacent only to a payer demanding RWE the protocol cannot generate; Pause the pathway is the honest Pharma & Life Sciences call. 3. A biologics company planning a biosimilar pathway already contained a payer demanding RWE the protocol cannot generate before phase-3 protocol with endpoint-sensitivity issues arrived; no new Clinical and Evidence Strategy path. 4. Provenance on phase-3 protocol with endpoint-sensitivity issues after a payer demanding RWE the protocol cannot generate is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a payer demanding RWE the protocol cannot generate. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read phase-3 protocol with endpoint-sensitivity issues against a payer demanding RWE the protocol cannot generate and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (phase-3 protocol with endpoint-sensitivity issues after a payer demanding RWE the protocol cannot generate). The follow-on Clinical and Evidence Strategy action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in phase-3 protocol with endpoint-sensitivity issues, then the action for clinical-development physician - Hypothesis scorecard against phase-3 protocol with endpoint-sensitivity issues: supported / rejected / untestable - Clinical and Evidence Strategy finding in phase-3 protocol with endpoint-sensitivity issues that a second reviewer can re-perform - Missing page in phase-3 protocol with endpoint-sensitivity issues after a payer demanding RWE the protocol cannot generate, if any